Preoperative transarterial chemoembolization does not improve the outcomes of resectable hepatocellular carcinoma: A propensity score-matched study
Background: Transarterial chemoembolization (TACE) is reserved for the treatment of intermediate hepatocellular carcinoma (HCC) (Barcelona Clinic Liver Cancer stage B); however, it can also be utilized as a neoadjuvant treatment prior to surgical resection in resectable HCC cases. This study aimed t...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Society of Gastrointestinal Intervention
2023-10-01
|
| Series: | International Journal of Gastrointestinal Intervention |
| Subjects: | |
| Online Access: | https://www.ijgii.org/journal/view.html?doi=10.18528/ijgii230025 |
| _version_ | 1797641848534073344 |
|---|---|
| author | Pipit Burasakarn Sermsak Hongjinda Anuparp Thienhiran Nichaphat Phancharoenkit Pusit Fuengfoo |
| author_facet | Pipit Burasakarn Sermsak Hongjinda Anuparp Thienhiran Nichaphat Phancharoenkit Pusit Fuengfoo |
| author_sort | Pipit Burasakarn |
| collection | DOAJ |
| description | Background: Transarterial chemoembolization (TACE) is reserved for the treatment of intermediate hepatocellular carcinoma (HCC) (Barcelona Clinic Liver Cancer stage B); however, it can also be utilized as a neoadjuvant treatment prior to surgical resection in resectable HCC cases. This study aimed to clarify the benefits of TACE in patients with resectable HCC. Methods: Data were retrospectively collected from patients with resectable HCC who had undergone hepatectomy between January 2010 and December 2015. A 1:1 propensity-matched case-control study was conducted using a logistic regression model that included the following covariates: sex, age, Model for end-stage liver disease score, and the number and size of tumors. Results: Of 160 patients, 37 and 123 were included in the TACE before liver resection (TACE-LR) and upfront LR groups, respectively. After 1:1 propensity score matching in the LR-matched group (n = 37), no significant differences in baseline parameters were found between the TACE-LR and LR-matched groups. Moreover, there were no significant differences in short-term outcomes, including intraoperative blood loss (800 mL vs. 500 mL, P = 0.148), operative time (300 min vs. 290 min, P = 0.824), and overall morbidity (24.3% vs. 13.51%, P = 0.235) between the TACE-LR and LR-matched groups. As long-term outcomes, no significant between-group differences were found in the 5-year disease-free survival rate (TACE-LR, 38%; LR, 58%; P = 0.89) or the 5-year overall survival rate (TACE-LR, 80.9%; LR, 80.8%; P = 0.72). Conclusion: The short- and long-term outcomes were not significantly different between preoperative TACE and LR for resectable HCC. |
| first_indexed | 2024-03-11T13:51:37Z |
| format | Article |
| id | doaj.art-d57c04a945034bb8bf59cee21021c2ea |
| institution | Directory Open Access Journal |
| issn | 2636-0004 |
| language | English |
| last_indexed | 2024-03-11T13:51:37Z |
| publishDate | 2023-10-01 |
| publisher | Society of Gastrointestinal Intervention |
| record_format | Article |
| series | International Journal of Gastrointestinal Intervention |
| spelling | doaj.art-d57c04a945034bb8bf59cee21021c2ea2023-11-02T08:36:06ZengSociety of Gastrointestinal InterventionInternational Journal of Gastrointestinal Intervention2636-00042023-10-0112416917510.18528/ijgii230025ijgii230025Preoperative transarterial chemoembolization does not improve the outcomes of resectable hepatocellular carcinoma: A propensity score-matched studyPipit Burasakarn0Sermsak Hongjinda1Anuparp Thienhiran2Nichaphat Phancharoenkit3Pusit Fuengfoo4Division of Hepato-Pancreato-Biliary Surgery, Department of Surgery, Phramongkutklao Hospital, Bangkok, ThailandDivision of Hepato-Pancreato-Biliary Surgery, Department of Surgery, Phramongkutklao Hospital, Bangkok, ThailandDivision of Hepato-Pancreato-Biliary Surgery, Department of Surgery, Phramongkutklao Hospital, Bangkok, ThailandDivision of Hepato-Pancreato-Biliary Surgery, Department of Surgery, Phramongkutklao Hospital, Bangkok, ThailandDivision of Hepato-Pancreato-Biliary Surgery, Department of Surgery, Phramongkutklao Hospital, Bangkok, ThailandBackground: Transarterial chemoembolization (TACE) is reserved for the treatment of intermediate hepatocellular carcinoma (HCC) (Barcelona Clinic Liver Cancer stage B); however, it can also be utilized as a neoadjuvant treatment prior to surgical resection in resectable HCC cases. This study aimed to clarify the benefits of TACE in patients with resectable HCC. Methods: Data were retrospectively collected from patients with resectable HCC who had undergone hepatectomy between January 2010 and December 2015. A 1:1 propensity-matched case-control study was conducted using a logistic regression model that included the following covariates: sex, age, Model for end-stage liver disease score, and the number and size of tumors. Results: Of 160 patients, 37 and 123 were included in the TACE before liver resection (TACE-LR) and upfront LR groups, respectively. After 1:1 propensity score matching in the LR-matched group (n = 37), no significant differences in baseline parameters were found between the TACE-LR and LR-matched groups. Moreover, there were no significant differences in short-term outcomes, including intraoperative blood loss (800 mL vs. 500 mL, P = 0.148), operative time (300 min vs. 290 min, P = 0.824), and overall morbidity (24.3% vs. 13.51%, P = 0.235) between the TACE-LR and LR-matched groups. As long-term outcomes, no significant between-group differences were found in the 5-year disease-free survival rate (TACE-LR, 38%; LR, 58%; P = 0.89) or the 5-year overall survival rate (TACE-LR, 80.9%; LR, 80.8%; P = 0.72). Conclusion: The short- and long-term outcomes were not significantly different between preoperative TACE and LR for resectable HCC.https://www.ijgii.org/journal/view.html?doi=10.18528/ijgii230025carcinomahepatocellular; chemoembolizationtherapeutic; general surgery; survival; treatment outcome |
| spellingShingle | Pipit Burasakarn Sermsak Hongjinda Anuparp Thienhiran Nichaphat Phancharoenkit Pusit Fuengfoo Preoperative transarterial chemoembolization does not improve the outcomes of resectable hepatocellular carcinoma: A propensity score-matched study International Journal of Gastrointestinal Intervention carcinoma hepatocellular; chemoembolization therapeutic; general surgery; survival; treatment outcome |
| title | Preoperative transarterial chemoembolization does not improve the outcomes of resectable hepatocellular carcinoma: A propensity score-matched study |
| title_full | Preoperative transarterial chemoembolization does not improve the outcomes of resectable hepatocellular carcinoma: A propensity score-matched study |
| title_fullStr | Preoperative transarterial chemoembolization does not improve the outcomes of resectable hepatocellular carcinoma: A propensity score-matched study |
| title_full_unstemmed | Preoperative transarterial chemoembolization does not improve the outcomes of resectable hepatocellular carcinoma: A propensity score-matched study |
| title_short | Preoperative transarterial chemoembolization does not improve the outcomes of resectable hepatocellular carcinoma: A propensity score-matched study |
| title_sort | preoperative transarterial chemoembolization does not improve the outcomes of resectable hepatocellular carcinoma a propensity score matched study |
| topic | carcinoma hepatocellular; chemoembolization therapeutic; general surgery; survival; treatment outcome |
| url | https://www.ijgii.org/journal/view.html?doi=10.18528/ijgii230025 |
| work_keys_str_mv | AT pipitburasakarn preoperativetransarterialchemoembolizationdoesnotimprovetheoutcomesofresectablehepatocellularcarcinomaapropensityscorematchedstudy AT sermsakhongjinda preoperativetransarterialchemoembolizationdoesnotimprovetheoutcomesofresectablehepatocellularcarcinomaapropensityscorematchedstudy AT anuparpthienhiran preoperativetransarterialchemoembolizationdoesnotimprovetheoutcomesofresectablehepatocellularcarcinomaapropensityscorematchedstudy AT nichaphatphancharoenkit preoperativetransarterialchemoembolizationdoesnotimprovetheoutcomesofresectablehepatocellularcarcinomaapropensityscorematchedstudy AT pusitfuengfoo preoperativetransarterialchemoembolizationdoesnotimprovetheoutcomesofresectablehepatocellularcarcinomaapropensityscorematchedstudy |